Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Case-reporting of acute hepatitis B and C among injection drug users.

Hagan H, Snyder N, Hough E, Yu T, McKeirnan S, Boase J, Duchin J.

J Urban Health. 2002 Dec;79(4):579-85.

2.

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain.

Santana Rodríguez OE, Malé Gil ML, HernándezSantana JF, Limiñana Cañal JM, Martín Sánchez AM.

Eur J Epidemiol. 1998 Sep;14(6):555-61.

PMID:
9794122
3.

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L.

Lancet. 2011 Aug 13;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0. Epub 2011 Jul 27. Review.

4.

Surveillance for acute viral hepatitis - United States, 2007.

Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC).

MMWR Surveill Summ. 2009 May 22;58(3):1-27.

6.

Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.

Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M.

BMC Infect Dis. 2006 Jun 8;6:93.

7.

Syringe exchange and risk of infection with hepatitis B and C viruses.

Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER.

Am J Epidemiol. 1999 Feb 1;149(3):203-13.

PMID:
9927214
8.

A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.

Removille N, Origer A, Couffignal S, Vaillant M, Schmit JC, Lair ML.

BMC Public Health. 2011 May 19;11:351. doi: 10.1186/1471-2458-11-351.

9.
10.

HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.

Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M.

Int J Infect Dis. 2010 Jan;14(1):e28-33. doi: 10.1016/j.ijid.2009.03.002. Epub 2009 May 21.

11.

Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.

Tun W, Vu L, Adebajo SB, Abiodun L, Sheehy M, Karlyn A, Njab J, Ahonsi B, Issa BK, Idogho O.

Int J STD AIDS. 2013 Aug;24(8):619-25. doi: 10.1177/0956462413477553. Epub 2013 Jul 19.

PMID:
23970571
12.

Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.

Devi KhS, Brajachand N, Singh HL, Singh YM.

J Commun Dis. 2005 Mar;37(1):73-7.

PMID:
16637404
13.

The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam.

Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, Coutinho R, Prins M.

Addiction. 2012 Mar;107(3):614-23. doi: 10.1111/j.1360-0443.2011.03654.x.

PMID:
21919987
14.
15.

Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013.

Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, Tressler S, Vellozzi C.

MMWR Morb Mortal Wkly Rep. 2016 Jan 29;65(3):47-50. doi: 10.15585/mmwr.mm6503a2.

16.

The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital, 1971-1975.

Thomson JA, Rodger AJ, Thompson SC, Jolley D, Byrne A, Best SJ, Crofts N.

Med J Aust. 1998 Oct 5;169(7):360-3.

PMID:
9803247
17.

Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992-2007.

Thein HH, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ.

J Viral Hepat. 2011 Jul;18(7):e232-41. doi: 10.1111/j.1365-2893.2011.01440.x. Epub 2011 Feb 17.

PMID:
21692938
18.

Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT).

Garfein RS, Swartzendruber A, Ouellet LJ, Kapadia F, Hudson SM, Thiede H, Strathdee SA, Williams IT, Bailey SL, Hagan H, Golub ET, Kerndt P, Hanson DL, Latka MH; DUIT Study Team.

Drug Alcohol Depend. 2007 Nov;91 Suppl 1:S4-17. Epub 2007 Jun 19.

PMID:
17582705
19.

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL.

J Viral Hepat. 2011 Sep;18 Suppl 1:1-16. doi: 10.1111/j.1365-2893.2011.01499.x.

20.

Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots.

Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, Ncube F, Parry JV.

J Viral Hepat. 2011 Apr;18(4):262-70. doi: 10.1111/j.1365-2893.2010.01297.x.

PMID:
20456636

Supplemental Content

Support Center